Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial

Paul, C.; Reich, Kristian; Gottlieb, Alice B.; Mrowietz, Ulrich; Philipp, Sandra; Nakayama, Juichiro; Harfst, E.; Guettner, A.; Papavassilis, Charis

doi:10.1111/jdv.12359

Cited by 78 publications

(59 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other clinical trials and subanalyses confirmed the preliminary data about safety and efficacy of secukinumab both in the short-and long-term [75][76][77][78][79].…”

Section: Agents Targeting Il-17 (Secukinumab Brodalumab and Ixekizumab)supporting

confidence: 72%

Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015)

Chiricozzi

Saraceno

Novelli

et al. 2016

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Though the recent introduction of new antipsoriatic agents has facilitated the management of long-term psoriasis, there is still a strong desire for alternative therapeutic options. Indeed, there remain unmet needs regarding safety and efficacy of psoriasis treatment that should be addressed. In this context, recently patented drugs may prove valid, interesting, and promising within the therapeutic paradigm.

show abstract

“…Other clinical trials and subanalyses confirmed the preliminary data about safety and efficacy of secukinumab both in the short-and long-term [75][76][77][78][79].…”

Section: Agents Targeting Il-17 (Secukinumab Brodalumab and Ixekizumab)supporting

confidence: 72%

Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015)

Chiricozzi

Saraceno

Novelli

et al. 2016

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

show abstract

“…The effect of body weight on treatment response rates showed slightly higher PASI 75 responses in patients weighing less than 90 kg than in those weighing more than 90 kg. Patients from that study who had involvement of hands, feet, or nails were analyzed in a post-hoc study 51. Altogether, 131 patients were included because of involvement of hands and/or feet, and 304 patients were included because of psoriasis of the fingernails.…”

Section: Efficacy In Trials Of Brodalumab Secukinumab and Ixekizumabmentioning

confidence: 99%

Targeting of interleukin-17 in the treatment of psoriasis

Lønnberg

Zachariae

Skov

2014

CCID

View full text Add to dashboard Cite

“Psoriasis” is a chronic immune-mediated inflammatory disorder with epidermal hyperplasia. There is some evidence that the cytokine interleukin-17A (often known as IL-17), which is mainly produced by Th17 cells, has a role in the pathogenesis of psoriasis. “IL-17” is a pro-inflammatory cytokine mainly important in the host’s defense against extracellular bacteria and fungi. The three new therapies with biologic drugs – brodalumab, secukinumab, and ixekizumab – all target the IL-17 signaling pathway. Secukinumab and ixekizumab neutralize IL-17A, while brodalumab blocks its receptor. Results from clinical trials have shown marked improvements in disease severity in patients with moderate-to-severe plaque psoriasis, using any of these three drugs. The biologic agents were generally well tolerated, but the duration of the trials was relatively short. In this review, we focus on the role of the IL-17 cytokine family in the pathogenesis of psoriasis; the efficacy, safety, and tolerability of brodalumab, secukinumab, and ixekizumab in clinical trials; and possible differences between targeting of the IL-17A receptor and targeting of the IL-17A ligand.

show abstract

“…The effect of body weight on treatment response rates showed slightly higher PASI 75 responses in patients weighing < 90 kg than in those weighing > 90 kg. Patients from that study who had involvement of hands, feet or nails were analyzed in a post-hoc study [32,33]; 131 patients because of involvement of hands and/or feet, and 304 because of psoriasis of the fingernails. There were clinically relevant improvements in hand and foot involvement after 12 weeks of treatment with secukinumab using the early regimen.…”

Section: Phase II Studiesmentioning

confidence: 99%

Secukinumab (AIN457) for the treatment of psoriasis

López‐Ferrer

Vilarrasa

Puig³

2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease with a multifactorial origin that appears in patients with genetic predisposition and is induced by environmental factors, and characterized by alterations in the innate and adaptive immunity. IL-17A is one of the specific cytokines involved in the pathogenesis of psoriasis and its inhibition is highly effective in the treatment of patients with moderate and severe psoriasis. Secukinumab is a monoclonal antibody that specifically binds to IL-17A and inhibits the interaction to its receptor, and it has demonstrated its efficacy and safety in the treatment of psoriasis. Phase II and III clinical trials indicate that > 80% of the patients receiving secukinumab achieve Psoriasis Area Severity Index (PASI) 75 at week 12. In the Phase III efficacy of response and safety of two fixed secukinumab regimens in psoriasis trial, PASI 75 rates were 81.6% with 300 mg secukinumab, 71.6% with 150 mg secukinumab and 4.5% with placebo, and responses were maintained up to 52 weeks in the majority of patients. In the Phase III Full Year Investigative Examination Of Secukinumab versus Etanercept Using Two Dosing Regimens To Determine Efficacy in Psoriasis study, the efficacy of secukinumab was compared to etanercept. The results indicate that both doses of secukinumab (150 and 300 mg) showed superior efficacy compared with etanercept throughout the study; PASI 75 rates at week 12 were 77.1% with 300 mg secukinumab, 67% with 150 mg of secukinumab, 44% with etanercept and 4.9% with placebo. PASI 90 and PASI 100 were 54 and 24% with secukinumab 300 mg and 21 and 4% with etanercept at week 12. At week 52, PASI 90 continued to be higher in the secukinumab group (65%) compared with the etanercept group (33%). Regarding safety, the most common side effects were nasopharyngitis and headache. The rate of infections was higher with secukinumab than placebo. This was especially the case for Candida infections, which were more common in the secukinumab group (4.7% with secukinumab 300 mg and 2.3% with secukinumab 150 mg), but all cases were resolved with conventional treatment. Secukinumab is a well-tolerated treatment that has demonstrated efficacy in treating moderate-to-severe plaque psoriasis. Nevertheless, long-term studies are necessary to confirm Phase II and Phase III data.

show abstract

Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial

Abstract: Secukinumab demonstrated a beneficial effect on psoriasis of the hands/feet/nails in this short-term assessment.

Cited by 78 publications

References 24 publications

Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015)

Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015)

Targeting of interleukin-17 in the treatment of psoriasis

Secukinumab (AIN457) for the treatment of psoriasis

Contact Info

Product

Resources

About